ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

NCAB Approves Plan for Public Participation Hearings Around U.S.

February 20, 1987

New Jersey Center Takes Slice of DOE Budget for Cancer

January 8, 1988

MGI Pharma, MethylGene Begin Phase II Trial Of MG98.

September 28, 2001

STAR Begins: Critics of Trial Call For Including A Placebo Arm

June 4, 1999

PROPOC Study Analyses Six Cancer DRGs

January 17, 1986

Commission Seeks Comparative Data on Cervical Cancer

August 16, 1991